Skip to main content

Table 4 Noncompartmental pharmacokinetics in plasma following single dosing with GSK933776 a

From: Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study

 

Geometric mean (CV in %)

Parameters

1 mg/kg ( N/n = 6/6)

95% CI

3 mg/kg ( N/n = 6/6)

95% CI

6 mg/kg ( N/n = 6/6)

95% CI

AUC0–12 (h∙mg/ml)

0.2 (26.0)

0.1 to 0.2

1.0 (19.5)

0.9 to 1.3

1.6 (20.6)

1.3 to 2.0

AUC0–t (h∙mg/ml)

3.3 (39.3)

2.2 to 4.9

23.0 (12.8)

20.2 to 26.3

36.3 (15.3)

31.0 to 42.6

C max (μg/ml)

18.4 (29.0)

13.6 to 24.9

104.0 (20.0)

84.4 to 128.1

158.2 (24.0)

123.8 to 202.1

C t (μg/ml)

0.5 (366.0)

0.1 to 2.5

1.2 (33.0)

0.9 to 1.7

1.5 (30.0)

1.1 to 2.1

t last (h)

909.8 (105.5)

367.0 to 2,255.4

1,337.4 (0.2)

1,335.1 to 1,339.8

1,417.2 (7.0)

1,317.6 to 1,524.3

t max (h)

11.7 (264.1)

2.6 to 53.1

2.1 (16.4)

1.8 to 2.5

1.9 (61.2)

1.1 to 3.4

  1. aAUC0–12: Area under the plasma concentration–time curve from time 0 to 12 hours postdosing; AUC0–t : Area under the plasma concentration–time curve to the last quantifiable concentration; CI: Confidence interval; C max: Maximum plasma concentration; C t: Concentration at t last; CV: Coefficient of variation; t last: Time of last observed plasma concentration; t max: Time of occurrence of C max.
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193